Ad Hoc: Epigenomics AG (FRA:ECX) : Ad Hoc Announcement According To §15 WpHG (German Securities Trading Act): Epigenomics AG (FRA:ECX) And Philips Collaborate On Integrated Automation Solutions For DNA Methylation-based Cancer Diagnostics

Epigenomics AG (FRA:ECX) Epigenomics AG / Miscellaneous cooperation, License / Ad hoc: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG and Philips Collaborate on Integrated Automation Solutions for DNA Methylation-based Cancer Diagnostics Ad hoc announcement according to §15 WpHG processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------



Berlin, December 19, 2008 - Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A0BVT96) and Royal Philips Electronics (NYSE: PHG, AEX: PHI) today entered into a collaboration and licensing agreement focusing on novel technologies and methods targeted at the diagnosis of various cancers. Under the agreement both parties will jointly perform feasibility studies aimed at developing an integrated and fully automated instrument platform for the diagnosis of certain cancers based on DNA methylation biomarkers. In addition, Philips obtained the option to license the required technologies and biomarkers separately or in combination for diagnostic applications. The option may be exercised upon the successful completion of the feasibility studies. Financial details are not disclosed.

End of ad hoc

Contact:

Epigenomics AG Dr. Achim Plum Sen. VP Corporate Development Kleine Praesidentenstr. 1 10178 Berlin Germany +49 30 24345 368 (phone) +49 30 24345 555 (fax) achim.plum@epigenomics.com www.epigenomics.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
--- End of Message ---

Epigenomics AG Kleine Präsidentenstr.1 Berlin Germany

WKN: A0BVT9; ISIN: DE000A0BVT96; Index: CDAX, Prime All Share, TECH All Share; Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;

Epigenomics AG

http://www.epigenomics.de

ISIN: DE000A0BVT96

Stock Identifier: XFRA.ECX